Status message

Not the entire site translated, but only to "Journal"

The diagnosis and treatment of depression in the various nosological categories

E.G.Kostyukova
Moscow Research Institute of Psychiatry, branch of Federal Medical Research Centre of Psychiatry and Narcology of Ministry of Healthcare of the Russian Federation, Russia, Moscow

Summary. Depression is transnosological syndrome, and a diagnosis and therapy of depressions within various nosological categories are often difficult and debating. On the basis of literature data, own research and clinical experience diagnostic problems and a systematics of depressions are discussed. The algorythm of patient examination and management with depression is offered. Data on comparative antidepressant efficacy in recurrent depressive disorder are shortly discussed. The differences in approaches to treatment of depression in recurrent depressive disorder, bipolar disorder and schizophrenia are described.

References: 
  • 1. Reed G.M., Correia J.M., Esparza P., Saxena S., Maj M. The WPA-WHO global survey of psychiatrists’ attitudes towards mental disorders classification // World Psychiatry. – 2011. – Vol. 10, No. 2. – P. 118–131.
  • 2. Mosolov C.N. Trevozhnye i depressivnye rasstroistva (komorbidnost' i terapiya). – M., 2007.
  • 3. Tan T.L., Kales J.D., Kales A., Soldatos C.R., Bixler, E.D. Biopsychobehavioral correlates of insomnia, IV: Diagnosis based on DSM-III // American Journal of Psychiatry. – 1984. – Vol. 141. – P. 357–362.
  • 4. Kielholz P. Psychiatrische pharmakotherapie in klinik und praxis. – Bern, Stuttgart, 1965. – 293 S.
  • 5. Mosolov S.N. Klinicheskoe primenenie antidepressantov // Meditsinskoe informatsionnoe agentstvo. – SPb., 1995. – 566 s.
  • 6. Sartorius N., Baghai T.C., Baldwin D.S. et al. Antidepressant medications and other treatment of depressive disorders: a cinp task based on review of evidence // The International Journal of Neuropsychopharmacology. – 2007. – Vol. 10, S 1. – P. 1–207.
  • 7. Bauer M., Pfennig A., Severus E., Whybrow P.C., Angst Ju., Möller H.J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders. Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders // World J Biol Psychiatry. – 2013. – Vol. 14, No. 5. – P. 334–385.
  • 8. Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996,
  • 9. Kostyukova E.G. Affektivnye rasstroistva // Psikhiatriya. Spravochnik prakticheskogo vracha / pod red. A.G. Gofmana. – M., 2006. – S. 142–166.
  • 10. Mosolov S.N., Kostyukova E.G., Ladyzhenskii M.Ya. Algoritm biologicheskoĭ terapii ostrogo epizoda rekurrentnogo depressivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2016. – № 3. – S. 27–40.
  • 11. Kostyukova E.G. i dr. Sravnitel'naya effektivnost' fluvoksamina i amitriptilina pri lechenii umerennoi i tyazheloi depressii // Novye dostizheniya v terapii psikhicheskikh rasstroistv. – 2002. – S. 305–315.
  • 12. Mosolov S.N., Kostyukova E.G. Aktual'nye voprosy farmakoterapii depressii // Novye dostizheniya v terapii psikhicheskikh rasstroistv. – 2002. – S. 211–232.
  • 13. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability // J Affect Disord. –2000. – Vol. 58. – P. 19–36.
  • 14. Bech P., Cialdella P., Haugh M.C., Birkett M.A., Hours A., Boissel J.P., Tollefson G.D. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression // Br J Psychiatry. – 2000. – Vol. 176. – P. 421–428.
  • 15. Evidence Report on Treatment of Depression: Newer Pharmacotherapies / AHCPR (Agency for Health Care Policy and Research). – 1999. – San Antonio Evidence-Based Practice Center. – Washington, DC, AHCPR, Evidence-Based Practice Centers. – AHCPR. – pub. No. 99-E014.
  • 16. Peretti S., Judge R., Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors // Acta Psychiatr Scand. – 2000. – No. 403, Suppl. 2000. – P. 17–25.
  • 17. Simon G.E., VonKorff M., Heiligenstein J.H., Revicki D.A., Grothaus L., Katon W., Wagner E.H. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine versus tricyclic antidepressants // JAMA. – 1996. – Vol. 275. – P. 1897–1902.
  • 18. Mace S., Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression // Expert Opin Pharmacother. – 2000. – Vol. 1. – P. 917–933.
  • 19. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007. Comparative Effectiveness Review / RTI–UNC Evidence-based Practice Center Research Triangle Park, NC. AHRQ Publication No. 12-EHC012-EF. – 2011. – No. 46.
  • 20. Cipriani A., Furukawa T.A., Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis // Lancet. – 2009. – Feb. 28. – No. 373 (9665). – P. 746–758. – PMID: 191853.
  • 21. Flament M.F., Lane R.M., Zhu R. et al. Predictors of an acute antidepressant response to fluoxetine and sertraline // Int Clin Psychopharmacol. – 1999. – Sep. – No. 14 (5). – P. 259–275.
  • 22. Mosolov S.N., Kostyukova E.G. i dr. Klinicheskaya effektivnost' i perenosimost' preparata estsitalopram pri lechenii umerennoi i tyazheloi depressii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2007. – № 2. – S. 42–48.
  • 23. Kostyukova E.G., Mosolov S.N. Differentsirovannyi podkhod k primeneniyu antidepressantov. Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 3. – S. 2–12.
  • 24. Mosolov S.N. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Politicheskaya mysl', 2012.
  • 25. Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. – SPb.: Beresta, 2012. – 448 s.
  • 26. Rush A.J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: STAR*D report // Am J Psychiatry. – Vol. 163. – P. 1905–1917.
  • 27. Neznanov N.G., Mazo G.E., Kozlova S.N., Krizhanovskii A.S. Ot razrabotki endofenomenologicheskoi klassifikatsii depressii k differentsirovannomu naznacheniyu antidepressivnoi terapii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013.– № 4. – S. 2–8.
  • 28. Mosolov S.N. Klinicheskaya diagnostika i farmakoterapiya depressii v somaticheskoi praktike // Terapevticheskii arkhiv. – 1999. – T. 71, № 10. – S. 70–76.
  • 29. Differentsirovannaya terapiya postpsikhoticheskikh depressii i depressivno-bredovykh sostoyanii u bol'nykh shizoaffektivnym psikhozom // Affektivnye i shizoaffektivnye psikhozy. – M., 1998. – S. 395–403.
  • 30. Malhi G.S. et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders // Australian and New Zealand Journal of Psychiatry. – 2015. – Vol. 49, No. 12. – P. 1087–1206. – DOI: 10.1177/0004867415617657
  • 31. Nazer L.H., Shankar G., Ali B.A.-H. et al. Fatal agranulocytosis associated with psychotropic medication use // American Journal of Health-System Pharmacy. – 2012. – Vol. 69. – P. 863–837.
  • 32. Flanagan R.J., Dunk L. Haematological toxicity of drugs used in psychiatry // Human Psychopharmacology. –2008. – Vol. 23, Suppl. 1. – P. 27–41.
  • 33. Franzini M., Fornaciari I., Vico T. et al. High-sensitivity gamma-glutamyltransferase fraction pattern in alcohol addicts and abstainers // Drug and Alcohol Dependence. – 2013. – Vol. 127. – P. 239–242.
  • 34. Beach S.R., Celano C.M., Noseworthy P.A. et al. QTc prolongation, torsades de pointes, and psychotropic medications // Psychosomatics. – 2013. – P. 1–13.
  • 35. Ellingrod V.L. Which psychotropics carry the greatest risk of QTc prolongation? // Current Psychiatry. – 2012. – Vol. 11. – P. 36–39.
  • 36. Camm A.J., Karayal O.N., Meltzer H. et al. Ziprasidone and the corrected QT interval: A comprehensive summary of clinical data // CNS Drugs. – 2012. – Vol. 26. – P. 351–365.
  • 37. Suzuki Y., Fukui N., Watanabe J. et al. QT prolongation of the antip- sychotic risperidone is predominantly related to its 9-hydroxy metab-olite paliperidone // Human Psychopharmacology. – 2012. – Vol. 27. – P. 39–42.
  • 38. Hage M.P., Azar S.T. The link between thyroid function and depression // Journal of Thyroid Research. – 2012. – Available at: http://dx.doi.org/10.1155/2012/590648 (Accessed 5 November 2015).
  • 39. Anglin R.E., Samaan Z., Walter S.D. et al. Vitamin D deficiency and depression in adults: Systematic review and meta-analysis // The British Journal of Psychiatry. – 2013. – Vol. 202. – P. 100–107.
  • 40. Matharoo M.S., Malhi G., Hale A.S. Neuorology for Psychiatrists. – London: Taylor & Francis, 2000,
  • 41. Barbarino J.M., Kroetz D.L., Klein T.E. et al. PharmGKB summary: Very important pharmacogene information for human leukocyte antigen B // Pharmacogenetics and Genomic. – 2015. – Vol. 25. – P. 205–221.
  • 42. Hicks J.K., Swen J.J., Thorn C.F. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants // Clinical Pharmacology and Therapeutics. – 2013. – Vol. 93. – P. 402–408.
  • 43. Hicks J.K., Bishop J.R., Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors // Clinical Pharmacology and Therapeutics. – 2015. – Vol. 98. – P. 127–134.
  • 44. Morgan V.A., Waterreus A., Jablensky A. et al. People living with psychotic illness in 2010: The second Australian national survey of psychosis // Australian and New Zealand Journal of Psychiatry. – 2012. – Vol. 46. – P. 735–752.
  • 45. Siris S., Pollack S., Bermanzohn P., Stronger R. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia // Schizophr Res. – 2000. – Vol. 44. – P. 187–192.
  • 46. Mosolov S.N., Tsukarzi E.E., Alfimov P.V. Algoritmy biologicheskoi terapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 1. – C. 27–36.
  • 47. Birchwood M. Pathways to emotional dysfunction in first-episode psychosis // The British Journal of Psychiatry. – 2003. – Vol. 182. – P. 373–375.
  • 48. Sins S.G. Assessment and treatment of depression in schizophrenia // Psychiatric Annals. – 1994. – Vol. 24 (9). – P. 463–467.
  • 49. Mulholland C., Cooper S. The symptom of depression in schizophrenia and its management // Adv Psychiatr Treat. – 2000. – Vol. 6. – P. 169–177.
  • 50. Johnson J., Horwath E., Weisman M.M. The validity of major depression with psychotic features based on a community study // Archives of General Psychiatry. – 1991. – Vol. 48 (12). – P. 1075–1081.
  • 51. Ohayon M.M., Schatzberg A.F. Prevalence of depressive episodes with psychotic features in the general population // American Journal of Psychiatry. – 2002. – Vol. 159 (11). – P. 1855–1861.
  • 52. Coryell W., Pfohl B., Zimmerman M. The clinical and neuroendocrine features of psychotic depression // Journal of Nervous and Mental Disease. – 1984. – Vol. 172 (9). – P. 521.
  • 53. Wijkstra J., Lijmer J., Burger H., Cipriani A., Geddes J., Nolen W.A. Pharmacological treatment for psychotic depression // Cochrane Database of Systematic Reviews. – 2015. – Issue 7. – Art. No.: CD004044. – DOI: 10.1002/14651858.CD004044.pub4
  • 54. Kraepelin E. Manic Depressive Insanity and Paranoia. – Edinburgh: E & S. Livingstone, 1899.
  • 55. Malhi G., Parker G., Greenwood J. Structural and functional models of depression: from subtypes to substrates // Acta Psychiatr Scand. – 2005. – Vol. 111. – P. 94–105.
  • 56. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression // Neuron. – 2002. – Vol. 34. – P. 13–25.
  • 57. Mosolov S.N. Sovremennye biologicheskie gipotezy rekurrentnoi depressii (obzor) // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2012. – T. 112, № 11–2. – S. 29–40.
  • 58. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. – Geneva: WHO, 1992.
  • 59. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. – 5th Edition. – Washington DC: American Psychiatric Publishing, 2013.
  • 60. Barlow D.H., Allen L.B., Choate M.L. Toward a unified treatment for emotional disorders // Behavior Therapy. – 2004. – Vol. 35. – P. 205–230.
  • 61. Suppes T., Kelly D.I., Perla J.M. Challenges in the management of bipolar depression // J Clin Psychiatry. – 2005. – Vol. 66, Suppl. 5. – P. 11–16.
  • 62. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder // Am J Psychiatry. – 1992. – No. 149. – P. 999–1010.
  • 63. Swann A.C., Bowden C.L., Morris D. et al. Depression during mania. Treatment response to lithium or divalproex // Arch Gen Psychiatry. – 1997. – No. 54. – P. 37–42.
  • 64. Managing Bipolar Disorder in Clinical Practice. Second edition / ed. Eduard Vieta. – 2009. – P. 127.
  • 65. Goldberg J.F., Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up // J Affect Disord. – 2004. – No. 81. – P. 123–131.
  • 66. Kostyukova E.G., Mosolov S.N. Printsipy i instrumenty diagnostiki bipolyarnogo affektivnogo rasstroistva kak osnova ratsional'noĭ farmakoterapii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2015. – № 2. – S. 2–11.
  • 67. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) // Am J Psychiatry. – 2002. – Vol. 159, Suppl. 4. – P. 1–50.
  • 68. Kostyukova E.G., Mosolov S.N. Sovremennaya diagnostika i terapiya bipolyarnogo affektivnogo rasstroistva: ot dokazatel'nykh nauchnykh issledovanii k klinicheskoi praktike // Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike). – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 491–528.
  • 69. Mosolov S.N., Kostyukova E.G., Kuzavkova M.V. Bipolyarnoe affektivnoe rasstroistvo. Diagnostika i terapiya. – M: Medpress-inform, 2008. – S. 383.
  • 70. Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression // Psychiatr Serv. – 2001. – Vol. 52. – P. 51–55.
  • 71. Akiskal H.S., Pinto O. The evolving bipolar spectrum: prototypes I, II, III, and IV // Psychiatr Clin North Am. – 1999. – No. 22. – P. 517–534.
  • 72. Mosolov S., Ushkalova A., Kostukova E., Shafarenko A., Alfimov P., Kostyukova A., Angst Ju. Bipolar II disorder in patients with a current diagnosis of recurrent depression // Bipolar Disorders. – 2014. – Vol. 16, No. 4. – P. 389–399.
  • 73. Mosolov S.N., Ushkalova A.V., Kostyukova E.G., Shafarenko A.A., Alfimov P.V., Kostyukova A.B. Diagnostika bipolyarnogo affektivnogo rasstroistva II tipa sredi patsientov s tekushchim diagnozom rekurrentnogo depressivnogo rasstroistva // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 2. – S. 2–14.
  • 74. Mosolov S.N., Ushkalova A.V., Kostiukova E.G., Shafarenko A.A. Maintenance treatment in patients with bd-ii misdiagnosed as rdd in russia // Bipolar Disorders. – 2014. – Vol. 16, No. S2. – S. 73–74.
  • 75. Kostyukova E.G., Shafarenko A.A., Ladyzhenskii M.Ya. Problemy i novye vozmozhnosti differentsirovannoi terapii bol'nykh bipolyarnym rasstroistvom // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 4. – S. 8–15.
  • 76. Mitchell P.B., Goodwin G.M., Johnson G.F., Hirschfeld R.M. Diagnostic guidelines for bipolar depression: a probabilistic approach // Bipolar Disord. – 2008, Feb. – Vol. 10 (1 Pt. 2). – P. 144–152.
  • 77. Suppes T., Leverich G.S., Keck P.E. et al. The Stanley Foundation Bipolar treatment outcome Network II. Demographics and illness characteristics of the first 261 patients // J Affect Disorder. – 2001. – Vol. 67. – P. 45–59.
  • 78. Grunze H., Vieta E., Goodwin G.M., Bowden Ch., Licht R.W., Möller H.J., Kasper S. et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression // The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. – 2010. – Vol. 11, No. 2. – P. 81–109.
  • 79. Antikonvul'santy v psikhiatricheskoi i nevrologicheskoi praktike / pod red. A.M. Veina, S.N. Mosolova. – SPb.: Medinfo, 1994.
  • 80. Kostyukova E.G., Mosolov S.N. Sovremennye podkhody k diagnostike, lecheniyu i profilaktike depressii pri bipolyarnom rasstroistve // Sotsial'naya i klinicheskaya psikhiatriya. – 2003. – T. 4. – S. 106–114.
  • 81. Post R.M., Denicoff K.D., Leverich G.S., Altshuler L.L. et al. Presentations of depression in bipolar illness // Clinical Neuroscience Research 2. – 2002. – Vol. 21. – P. 142–157.
  • 82. Ehnvall A., Agren H. Patterns of sensitisation in the course of affective illness. A life-charting study of treatment-refractory depressed patients // J Affect Disord. – 2002. – Vol. 70. – P. 67–75.
  • 83. Gijsman H.J., Geddes J.R., Rendell J.M. et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trails // Am J Psychiatry. – 2004. – Vol. 161. – P. 1537–1547.
  • 84. Mosolov S.N., Kostyukova E.G., Tsukarzi E.E. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu bipolyarnogo affektivnogo rasstroistva u vzroslykh (proekt) // Rossiiskoe obshchestvo psikhiatrov. 25.11.13. – URL: http://psychiatr.ru/news/183
  • 85. Ahlfors U.G. Neuroleptic-induced extrapyramidal side effects in bipolar and schizophrenic patients / Ahlfors U.G., Baastrup P.C., Dencker S.J. et al. // Acta Psychiatr Scand. – 1981. – Sep. – Vol. 64, No. 3. – P. 226–237.
  • 86. Malhi G.S., Parker G.B., Gladstone G. et al. (2002) Recognizing the anxious face of depression // Journal of Nervous and Mental Disorders. – Vol. 190. – P. 366–373.
  • 87. Insel T.R. The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry // American Journal of Psychiatry. – 2014. – Vol. 171. – P. 395–397.
  • 88. Buckholtz J.W., Meyer-Lindenberg A. Psychopathology and the human connectome: Toward a transdiagnostic model of risk for mental illness // Neuron. – 2012. – Vol. 74. – P. 990–1004.
  • 89. Papakostas G.I., Fan H., Tedeschini E. Severe and anxious depres- sion: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors // European Neuropsychopharmacology. – 2012. – Vol. 22. – P. 347–355.
  • 90. Souery D., Oswald P., Massat I. et al. Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study // Journal of Clinical Psychiatry. – 2007. – Vol. 68. – P. 1062–1070.
  • 91. Tollefson G.D., Holman S.L., Sayler M.E. et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features // Journal of Clinical Psychiatry. – 1994. – Vol. 55. – P. 50–59.
  • 92. Deckersbach T., Peters A.T., Sylvia L. et al. Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD // American Journal of Psychiatry. – 2014. – Vol. 171. – P. 178–186.
  • 93. Fawcett J., Barkin R.L. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety // Journal of Clinical Psychiatry. – 1998. – Vol. 59. – P. 123–127.
  • 94. Rudolph R.L., Entsuah R., Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression // Journal of Clinical Psychopharmacology. – 1998. – Vol. 18. – P. 136–144.
  • 95. Tourian K.A., Jiang Q., Ninan P.T. Analysis of the effect of des- venlafaxine on anxiety symptoms associated with major depressive disorder: Pooled data from 9 short-term, double-blind, placebo-con- trolled trials // CNS Spectrums. – 2010. – Vol. 15. – P. 187–193.
  • 96. Mulder R.T. Depression and personality disorder // Current Psychiatry Reports. – 2004. – Vol. 6. – P. 51–57.
  • 97. Friborg O., Martinsen E.W., Martinussen M. et al. Comorbidity of personality disorders in mood disorders: A meta-analytic review of 122 studies from 1988 to 2010 // Journal of Affective Disorders. – 2014. – Vol. 152. – P. 1–11.
  • 98. Newton-Howes G., Tyrer P., Johnson T. et al. Influence of personality on the outcome of treatment in depression: Systematic review and meta-analysis // Journal of Personality Disorders. – 2014. – Vol. 28. – P. 577–593.
  • 99. Mulder R.T., Joyce P.R., Luty S.E. The relationship of personality disorders to treatment outcome in depressed outpatients // Journal of Clinical Psychiatry. – 2003. – Vol. 64. – P. 259–264.
  • 100. Fava M., Farabaugh A.H., Sickinger A.H. et al. Personality disorders and depression // Psychological Medicine. – 2002. – Vol. 32. – P. 1049–1057.
  • 101. Mulder R.T., Joyce P.R., Frampton C.M. Personality disorders improve in patients treated for major depression // Acta Psychiatrica Scandinavica. – 2010. – Vol. 122. – P. 219–225.
  • 102. Niculescu A.B. Convergent functional genomics of psychiatric disorders // American Journal of Medical Genetics. Part B., Neuropsychiatric Genetics. – 2013. – Vol. 162. – P. 587–594.